Pharmacogenomics guidelines: Current status and future development

Chengxian Guo; Xiaoxue Xie; Jingao Li; Lihua Huang; Shaojun Chen; Xi Li; Xin Yi; Qin Wu; Guoping Yang; Honghao Zhou; Jun-Ping Liu; Xiang Chen

doi:10.1111/1440-1681.13097

Pharmacogenomics guidelines: Current status and future development

Clin Exp Pharmacol Physiol. 2019 Aug;46(8):689-693. doi: 10.1111/1440-1681.13097. Epub 2019 May 16.

Authors

Chengxian Guo¹, Xiaoxue Xie², Jingao Li³, Lihua Huang⁴, Shaojun Chen⁵, Xi Li⁶, Xin Yi⁶, Qin Wu⁶, Guoping Yang¹, Honghao Zhou^{7

8}, Jun-Ping Liu⁹, Xiang Chen^{10

11}

Affiliations

¹ Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
² Department of Radiation and Oncology, Hunan Provincial Tumor Hospital, The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, Hunan, China.
³ Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China.
⁴ Center for Medical Experiments, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
⁵ Department of Oncology, Fourth Affiliated Hospital, Guangxi Medical University, Liuzhou, Guangxi, China.
⁶ Hunan Normal University School of Medicine, Changsha, Hunan, China.
⁷ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
⁸ Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, China.
⁹ Institute of Aging Research, Hangzhou Normal University School of Medicine, Hangzhou, Zhejiang, China.
¹⁰ Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
¹¹ Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University, Changsha, Hunan, China.

PMID: 31009088
DOI: 10.1111/1440-1681.13097

Abstract

Genetic polymorphisms impact biological responses to drugs. Current pharmacogenomics guidelines formulated by different countries, such as the Clinical Pharmacogenetics Implementation Consortium, the Dutch Pharmacogenetics Working Group, the Canadian Pharmacogenomics Network for Drug Safety, and the French National Network (Réseau) of Pharmacogenetics, play important roles in clinical practices. However, the standards for these guidelines vary significantly, resulting in differences in recommendations. The present article discusses these differences by head-to-head comparison of the existing pharmacogenomics guidelines and proposes new strategies for their future development.

Keywords: guidelines; pharmacogenetics; pharmacogenomics.

Publication types

Review

MeSH terms

Guidelines as Topic*
Humans
Pharmacogenetics / methods*